Tyra Biosciences (TYRA) closed at $20.12 on November 20, 2026, up 2.0% from the previous close, on volume of 427,537 shares (30-day average 561,732).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Tyra Bioscience (TYRA)
TipRanks (Fri, 20-Nov 7:30 AM ET)
Tyra Biosciences: Buy Rating Reiterated as Dabogratinib Shows Promise; $27 Price Target Unchanged
TipRanks (Tue, 17-Nov 8:25 AM ET)
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
PRNewswire (Tue, 10-Nov 8:00 AM ET)
Tyra Biosciences to Participate in Upcoming Investor Conferences
PRNewswire (Thu, 5-Nov 4:05 PM ET)
PRNewswire (Thu, 15-Oct 10:01 AM ET)
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PRNewswire (Mon, 14-Sep 6:45 AM ET)
PRNewswire (Wed, 9-Sep 7:00 AM ET)
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
PRNewswire (Tue, 8-Sep 4:05 PM ET)
PRNewswire (Fri, 4-Sep 8:01 AM ET)
TYRA’s $383.5 Million Cash Position and Multiple Phase 2 Milestones Set Stage for Major Advances
Market Chameleon (Thu, 14-May 7:42 AM ET)
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Tyra Biosciences trades on the NASDAQ stock market under the symbol TYRA.
As of November 20, 2026, TYRA stock price climbed to $20.12 with 427,537 million shares trading.
TYRA has a beta of -0.37, meaning it tends to be less sensitive to market movements. TYRA has a correlation of 0.01 to the broad based SPY ETF.
TYRA has a market cap of $1.39 billion. This is considered a Small Cap stock.
In the last 3 years, TYRA traded as high as $40.65 and as low as $6.42.
The top ETF exchange traded funds that TYRA belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
TYRA has underperformed the market in the last year with a return of -4.2%, while the SPY ETF gained +6.9%. In the last 3 month period, TYRA fell short of the market, returning -21.7%, while SPY returned -9.3%. However, in the most recent 2 weeks TYRA has outperformed the stock market by returning -4.9%, while SPY returned -6.2%.
TYRA support price is $19.08 and resistance is $20.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TYRA shares will trade within this expected range on the day.